

will be posted to the docket at <http://www.regulations.gov>.

Dated: December 26, 2012.

Leslie Kux,

Assistant Commissioner for Policy.

[FR Doc. 2012-31478 Filed 12-31-12; 8:45 am]

BILLING CODE 4160-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2012-N-0001]

Advisory Committees; Tentative Schedule of Meetings for 2013

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing a tentative schedule of forthcoming meetings of its public advisory committees for 2013. During 1991, at the request of the Commissioner of Food and Drugs (the Commissioner), the

Institute of Medicine (the IOM) conducted a study of the use of FDA's advisory committees. In its final report, one of the IOM's recommendations was for the Agency to publish an annual tentative schedule of its meetings in the **Federal Register**. This publication implements the IOM's recommendation.

FOR FURTHER INFORMATION CONTACT:

Teresa L. Hays, Advisory Committee Oversight and Management Staff (HF-4), Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 32, rm. 5290, Silver Spring, MD 20993, 301-796-8220.

SUPPLEMENTARY INFORMATION: The IOM, at the request of the Commissioner, undertook a study of the use of FDA's advisory committees. In its final report in 1992, one of the IOM's recommendations was for FDA to adopt a policy of publishing an advance yearly schedule of its upcoming public advisory committee meetings in the **Federal Register**; FDA has implemented this recommendation. The annual publication of tentatively scheduled advisory committee meetings will provide both advisory committee

members and the public with the opportunity, in advance, to schedule attendance at FDA's upcoming advisory committee meetings. Because the schedule is tentative, amendments to this notice will not be published in the **Federal Register**. However, changes to the schedule will be posted on the FDA advisory committees' Internet site located at <http://www.fda.gov/AdvisoryCommittees/default.htm>. FDA will continue to publish a **Federal Register** notice 15 days in advance of each upcoming advisory committee meeting, to announce the meeting (21 CFR 14.20).

The following list announces FDA's tentatively scheduled advisory committee meetings for 2013. You may also obtain up-to-date information by calling the Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area) or on the FDA Internet Web site under our 2013 tentative scheduled meeting listing at <http://www.fda.gov/AdvisoryCommittees/Calendar/ucm153468.htm>.

TABLE 1

Committee name	Tentative date(s) of meeting(s)
OFFICE OF THE COMMISSIONER	
Pediatric Advisory Committee	March 14–15, September 19–20.
Risk Communication Advisory Committee	February 11–12, April 29–30, August 15–16, December 16–17.
Science Board to FDA	February 27, June 24, November 20.
CENTER FOR BIOLOGICS EVALUATION AND RESEARCH	
Allergenic Products Advisory Committee	November 5–6.
Blood Products Advisory Committee	February 12–13, April 8–9, August 1–2.
Cellular, Tissue and Gene Therapies Advisory Committee	January 15, April 17–18, June 27–28, October 24–25.
Transmissible Spongiform Encephalopathies Advisory Committee	March 14–15.
Vaccines and Related Biological Products Advisory Committee	February 27, May 8–9 or July 17–18 (Backup date), September 18–19, November 13–14.
CENTER FOR DRUG EVALUATION AND RESEARCH	
Anesthetic and Analgesic Drug Products Advisory Committee	Date(s), if needed, to be determined.
Anti-Infective Drugs Advisory Committee	Date(s), if needed, to be determined.
Antiviral Drugs Advisory Committee	May and October dates to be determined.
Arthritis Advisory Committee	July or August and fall dates to be determined.
Cardiovascular and Renal Drugs Advisory Committee	April 17 and other date(s) to be determined.
Dermatologic and Ophthalmic Drugs Advisory Committee	Date(s), if needed, to be determined.
Drug Safety and Risk Management Advisory Committee	January 24–25, March 5.
Endocrinologic and Metabolic Drugs Advisory Committee	January 10, July, and August dates to be determined.
Gastrointestinal Drugs Advisory Committee	March 19 and other date(s) to be determined.
Medical Imaging Drugs Advisory Committee	February 14 and May date to be determined.
Nonprescription Drugs Advisory Committee	Date(s), if needed, to be determined.
Oncologic Drugs Advisory Committee	April 5, May, June, July, September date(s) to be determined.
Pharmacy Compounding Drugs Advisory Committee	Date(s), if needed, to be determined.
Peripheral and Central Nervous System Drugs Advisory Committee	May 22.
Advisory Committee for Pharmaceutical Science and Clinical Pharmacology	Date(s), if needed, to be determined.
Psychopharmacologic Drugs Advisory Committee	Date(s), if needed, to be determined.
Pulmonary-Allergy Drugs Advisory Committee	January 29–30, March 7.
Advisory Committee for Reproductive Health Drugs	March 4–5, July 9.

TABLE 1—Continued

Committee name	Tentative date(s) of meeting(s)
CENTER FOR DEVICES AND RADIOLOGICAL HEALTH	
Medical Devices Advisory Committee (Comprised of 18 Panels)	
Anesthesiology and Respiratory Therapy Devices Panel	Date(s), if needed, to be determined.
Circulatory System Devices Panel	May 17, May 24, June 27, September 27, November 22.
Clinical Chemistry and Clinical Toxicology Devices Panel	April 25.
Dental Products Panel	Date(s), if needed, to be determined.
Ear, Nose, and Throat Devices Panel	July 12.
Gastroenterology-Urology Devices Panel	April 24, May 16.
General and Plastic Surgery Devices Panel	June 13.
General Hospital and Personal Use Devices Panel	June 28, August 30.
Hematology and Pathology Devices Panel	Date(s), if needed, to be determined.
Immunology Devices Panel	Date(s), if needed, to be determined.
Medical Devices Dispute Resolution Panel	Date(s), if needed, to be determined.
Microbiology Devices Panel	June 14.
Molecular and Clinical Genetics Panel	September 13.
Neurological Devices Panel	February 22.
Obstetrics and Gynecology Devices Panel	September 20.
Ophthalmic Devices Panel	June 14, August 23.
Orthopaedic and Rehabilitation Devices Panel	April 5, September 26.
Radiological Devices Panel	September 12.
Device Good Manufacturing Practice Advisory Committee	April 11.
National Mammography Quality Assurance Advisory Committee	October 25.
Technical Electronic Product Radiation Safety Standards Committee	Date(s), if needed, to be determined.
CENTER FOR FOOD SAFETY AND APPLIED NUTRITION	
Food Advisory Committee	July 15–16, August 29–30, September 23–24.
CENTER FOR TOBACCO PRODUCTS	
Tobacco Products Scientific Advisory Committee	Feb 11–12, April 30–May 1.
CENTER FOR VETERINARY MEDICINE	
Veterinary Medicine Advisory Committee	Date(s), if needed, to be determined.
NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH (NCTR)	
Science Advisory Board to NCTR	December 10–11.

Dated: December 26, 2012.

Leslie Kux,

Assistant Commissioner for Policy.

[FR Doc. 2012–31475 Filed 12–31–12; 8:45 am]

BILLING CODE 4160–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Proposed Collection; Comment Request (60-Day FRN); A Generic Submission for Formative Research, Pretesting, and Customer Satisfaction of NCI's Communication and Education Resources (NCI)

SUMMARY: Under the provisions of Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995, for opportunity for public comment on proposed data collection projects, the National Institutes of Health (NIH) will publish periodic summaries of proposed

projects to be submitted to the Office of Management and Budget (OMB) for review and approval.

Written comments and/or suggestions from the public and affected agencies are invited to address one or more of the following points: (1) Whether the proposed collection of information is necessary for the proper performance of the function of the agency, including whether the information will have practical utility; (2) The accuracy of the agency's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) The quality, utility, and clarity of the information to be collected; and (4) Minimize the burden of the collection of information on those who are to respond, including the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology.

To submit comments in writing, request more information on the proposed project, or to obtain a copy of the data collection plans and instruments, contact: Nina Goodman, Public Health Advisor, Office of Communications and Education (OCE), NCI, NIH, 6116 Executive Blvd., Suite 400, Rockville, MD 20892, call non-toll-free number (301) 435–7789 or email your request, including your address to: goodmann@mail.nih.gov.

Comments regarding this information collection are best assured of having their full effect if received within 60 days of the date of this publication.

Proposed Collection: A Generic Submission For Formative Research, Pretesting, and Customer Satisfaction of NCI's Communication and Education Resources, 0925–0046, Expiration Date 2/28/2013—EXTENSION—National Cancer Institute, National Institutes of Health (NIH).

Need and Use of Information Collection: In order to carry out NCI's